|
|
https://mb.cision.com/Public/18595/3670611/b35d1142fa4a1983_800x800ar.png
UCB Submits Response to FDA Complete Response Letter for Bimekizumab
Brussels Belgium, 22nd November 2022 =E2=80=93 18:30 CET =E2=80=93 UCB,=
a global biopharmaceutical company, today announced that it has resubmitte=
d the Biologics License Application BLA to the U.S. Food and Drug Adminis=
tration FDA for... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3666193/9cece37fb36d9bab_800x800ar.png
UCB announces U.S. FDA acceptance of new drug application and EMA MAA va=
lidation for zilucoplan for the treatment of generalized myasthenia gravis =
in adult patients
=C2=B7 New drug application NDA for zilucoplan seeks approval for the tre=
atment of generalized myasthenia gravis gMG in adult patients who are... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3664497/8a15d6f32cb1113b_800x800ar.png
Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phas=
e 3 Studies in Psoriatic Arthritis, NonRadiographic Axial Spondyloarthriti=
s and Ankylosing Spondylitis
=C2=B7 New latebreaking 52week data from Phase 3 bimekizumab investigatio=
nal studies in psoriatic arthritis and across the spectrum... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3663475/a3ca183b23c7b65b_800x800ar.png
UCB Reinforces Commitment to Rheumatology with 15 Abstracts including Ne=
w LateBreaking Data at ACR Convergence 2022
=C2=B7 Latebreaking 52week data on investigational bimekizumab in the tre=
atment of adults with active psoriatic arthritis and active axial spondyloa=
rthritis to be presented
=C2=B7 New data... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3636902/999776931e930491_800x800ar.png
FINTEPLA^=C2=AE=E2=96=BC fenfluramine Approved in Japan for the Treatm=
ent of Seizures Associated with Dravet Syndrome
=C2=B7 Approval supported by clinical trial data that showed when added to =
existing treatment regimens, fenfluramine significantly reduced monthly con=
vulsive seizure frequency compared to... See more |
|
|
|
| |
|
| |
|
|
Search :
